This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Nature Communications Open Access 10 June 2021
-
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Nature Communications Open Access 26 February 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev 1998; 12: 1610–1620.
Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K et al. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 2003; 17: 1–8.
Luo JM, Liu ZL, Hao HL, Wang FX, Dong ZR, Ohno R . Mutation analysis of SHIP gene in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12: 420–426.
Wang Z, Moult J . SNPs, protein structure, and disease. Hum Mutat 2001; 17: 263–270.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.
Shigematsu H, Gazdar AF . Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006; 118: 257–262.
Masri MA, Abdel Seed NM, Fahal AH, Romano M, Baralle F, El Hassam AM et al. Minor role for BRCA2 (exon11) and p53 (exon 5–9) among Sudanese breast cancer patients. Breast Cancer Res Treat 2002; 71: 145–147.
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617–1628.
Acknowledgements
We thank the Royal Hallamshire Hospital Leukaemia and Myeloma Research Fund for funding this work and Dr I Brock, University of Sheffield Cancer Studies Institute for DHPLC operation and analysis. The authors are grateful to Professor DC Linch and Mr S Langabeer for provision of DNA from patients entered into the Medical Research Council Trails AML X and XII.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gilby, D., Goodeve, A., Winship, P. et al. Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia 21, 2390–2393 (2007). https://doi.org/10.1038/sj.leu.2404864
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404864
This article is cited by
-
Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
Nature Communications (2021)
-
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma
Nature Communications (2013)
-
Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155
Oncogene (2012)
-
A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL)
Leukemia (2011)
-
Reduced proliferation of CD34+ cells from patients with acute myeloid leukemia after gene transfer of INPP5D
Gene Therapy (2009)